Journal of Alzheimer s Disease · 2017 · 103 citations · 57 references
MedicineNeurologyPsychologyCognitive PsychologyNeuropsychiatryNeuropsychologyCognitive AgingCognitive AssessmentCognitive DeclineCognitive ImpairmentCognitive SymptomsNeurocognitive AssessmentBrief Cognitive Screening InstrumentsCognitive ComplaintsCognitive Impairment DetectionCognitive Impairment EvaluationCognitive Status AssessmentCognitive Symptoms AssessmentMild Cognitive Impairment DiagnosisScreening Tool Comparison
BACKGROUND: Substantial studies have reported the prevalence and the affecting factors of subjective cognitive decline (SCD). The complaints screening scale has also been used for probing. However, little is known in China. OBJECTIVE: To investigate the prevalence and risk factors of SCD, and explore an SCD complaints screening scale in China. METHODS: Stratified cluster random sampling was conducted. 2,689 residents aged 60-80 years completed questionnaire 1. 814 residents were included for clinical and neuropsychological evaluations. Two standards were used to make the diagnosis of mild cognitive impairment (MCI) and SCD, and a preliminary screening rate comparison was carried out. Finally, we assessed the risk factors of SCD and the correlation between the SCD-questionnaire 9 (SCD-Q9) and the Auditory Verbal Learning Test-Long Delay Free Recall (AVLT-LR). RESULTS: 1) Standard 1 (ADNI2): the prevalence of SCD was 18.8% (95% CI = 14.7-22.9%) and zero conformed to six criteria (SCD plus). 2) Standard 2 (Jak/Bondi): the prevalence of SCD was 14.4% (95% CI = 10.7-18.1%). 3) Standard 1 had a relatively higher "false" positive rate, whereas Standard 2 had higher "false" negative rate. 4) Age, low education, fewer close friends, and daily drinking were independent risk factors for SCD progressing to MCI. 5) Total points of SCD-Q9 were negatively correlated to the value of AVLT-LR. CONCLUSIONS: The prevalence of SCD is high in the ShunYi District in Beijing, China. Age, low education, less social support, and daily drinking are independent risk factors. The brief SCD-Q9 can be used as a reference.
57
The Clinical Dementia Rating (CDR)
John C. Morris · Neurology · 1993 · 10K citations
Medicine, Neurology, Psychiatry +12
Cerebral Blood Flow in Dementia
Vladimir Hachinski, L. D. Iliff, E. Zilhka et al. · Archives of Neurology · 1975 · 3.2K citations
Medicine, Neurology, Neuroscience +14
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14